Jessica Cotrone - Evelo Biosciences VP Communications
| EVLODelisted Stock | USD 8.23 2.68 24.56% |
Insider
Jessica Cotrone is VP Communications of Evelo Biosciences
| Phone | 617 577 0300 |
| Web | https://www.evelobio.com |
Evelo Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.8325) % which means that it has lost $0.8325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (62.3276) %, meaning that it created substantial loss on money invested by shareholders. Evelo Biosciences' management efficiency ratios could be used to measure how well Evelo Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Evelo Biosciences currently holds 51.14 M in liabilities with Debt to Equity (D/E) ratio of 1.55, which is about average as compared to similar companies. Evelo Biosciences has a current ratio of 4.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Evelo Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evelo Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evelo Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evelo to invest in growth at high rates of return. When we think about Evelo Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Garcia | Surrozen | N/A | |
| Geoffrey Birkett | Ensysce Biosciences | 61 | |
| W Vernon | Nuvation Bio | 65 | |
| Sumita JD | Instil Bio | 50 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Eugene Jiang | ABVC Biopharma | 38 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Tracy Zimmermann | Generation Bio Co | 54 | |
| David Hanley | Nuvation Bio | 54 | |
| Stephanie Yao | Kronos Bio | N/A | |
| David Hale | Dermata Therapeutics | 75 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Diane Esq | Windtree Therapeutics | 55 | |
| MS MBA | Generation Bio Co | 46 | |
| Dr IV | Assembly Biosciences | 52 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Jeffrey Millard | Ensysce Biosciences | 48 | |
| Jonathan MD | Erasca Inc | 52 | |
| ChiHsin King | ABVC Biopharma | 76 | |
Management Performance
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 |
Evelo Biosciences Leadership Team
Elected by the shareholders, the Evelo Biosciences' board of directors comprises two types of representatives: Evelo Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evelo. The board's role is to monitor Evelo Biosciences' management team and ensure that shareholders' interests are well served. Evelo Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evelo Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Carriere, VP Officer | ||
| Mark Bodmer, Chief Scientific Officer and Presidentident of Research and Development | ||
| Jonathan Zung, Chief Officer | ||
| Leslie WardwellScott, VP Integration | ||
| Chun Zhang, Chief Officer | ||
| Julie Carretero, Chief Officer | ||
| Jessica Cotrone, VP Communications | ||
| Balkrishan Gill, CEO Pres | ||
| Kendra Sweeney, Head Markets | ||
| Marella Thorell, CFO Treasurer |
Evelo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evelo Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 18.93 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 83.13 % | ||||
| Number Of Shares Shorted | 430.1 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 3.51 X | ||||
| EBITDA | (108.41 M) |
Pair Trading with Evelo Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evelo Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evelo Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Evelo Pink Sheet
Moving against Evelo Pink Sheet
| 0.79 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.63 | DTIL | Precision BioSciences | PairCorr |
| 0.59 | VERU | Veru Inc Fiscal Year End 13th of December 2024 | PairCorr |
| 0.47 | VIGL | Vigil Neuroscience Downward Rally | PairCorr |
| 0.46 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Evelo Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evelo Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evelo Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evelo Biosciences to buy it.
The correlation of Evelo Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evelo Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evelo Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evelo Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Evelo Pink Sheet
If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |